Diffusion Pharmaceuticals Inc. (DFFN:LSE) Annual Reports & Investor Relations Material

Overview

Charlottesville-based biopharmaceutical company Diffusion Pharmaceuticals Inc. is making waves with its innovative oxygen delivery enhancing therapies. The firm's marquee product candidate, Trans Sodium Crocetinate, has been hailed as a potential game-changer for the treatment of COVID-19, thanks to its ability to greatly improve the diffusion of oxygen to bodily tissues. Founded in 2001, Diffusion Pharmaceuticals is at the forefront of a crucial sector of the healthcare industry that is focused on improving oxygen delivery to improve patient outcomes.

Annual Reports

Frequently Asked Questions

What is Diffusion Pharmaceuticals Inc.'s ticker?

Diffusion Pharmaceuticals Inc.'s ticker is DFFN

What exchange is Diffusion Pharmaceuticals Inc. traded on?

The company's shares trade on the LSE stock exchange

Where are Diffusion Pharmaceuticals Inc.'s headquarters?

They are based in Charlottesville, Virginia

How many employees does Diffusion Pharmaceuticals Inc. have?

There are 1-10 employees working at Diffusion Pharmaceuticals Inc.

What is Diffusion Pharmaceuticals Inc.'s website?

It is https://www.diffusionpharma.com/

What type of sector is Diffusion Pharmaceuticals Inc.?

Diffusion Pharmaceuticals Inc. is in the Healthcare sector

What type of industry is Diffusion Pharmaceuticals Inc.?

Diffusion Pharmaceuticals Inc. is in the Biotechnology industry

Who are Diffusion Pharmaceuticals Inc.'s peers and competitors?

The following five companies are Diffusion Pharmaceuticals Inc.'s industry peers:

- Surface Oncology

- Catalyst Biosciences, Inc.

- Aerpio Pharmaceuticals, Inc.

- Neurocrine Biosciences

- BeiGene, Ltd.